Cargando…
Bevacizumab for glioblastoma
Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves c...
Autor principal: | Narita, Yoshitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671800/ https://www.ncbi.nlm.nih.gov/pubmed/26664126 http://dx.doi.org/10.2147/TCRM.S58289 |
Ejemplares similares
-
Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013) -
ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
por: Kikuchi, Miyu, et al.
Publicado: (2021) -
Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011) -
Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010) -
Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)